South Africa currently has the highest incidence of TB per 100000 (358 per 100000) people in the world. In 2007 alone 112000 people died of TB in South Africa, of which 94 000 (72%) were co-infected with HIV. Although TB treatments exist, poor patient treatment compliance and drug resistance pose a great challenge to TB treatment programs worldwide. To improve the current inadequate therapeutic management of TB, a polymeric anti-TB nanodrug delivery system for anti-TB drugs was developed that may enable entry, targeting, sustained release over long periods and uptake of the antibiotics in the cells, hence reducing the dose frequency and simultaneously improving patient compliance.
Reference:
Lemmer, Y, Semete, B, Booysen, L et al. 2010. Targeted nanodrug delivery systems for the treatment of Tuberculosis. 3rd International CDTM symposium, Cardiff, UK, 26-28 June 2010, pp 1
Lemmer, Y., Semete, B., Booysen, L., Kalombo, L., Katata, L., Jones, A., ... Verschoor, J. (2010). Targeted nanodrug delivery systems for the treatment of Tuberculosis. http://hdl.handle.net/10204/4597
Lemmer, Yolandy, B Semete, L Booysen, Lonji Kalombo, L Katata, AT Jones, C Alexander, M Khati, HS Swai, and JA Verschoor. "Targeted nanodrug delivery systems for the treatment of Tuberculosis." (2010): http://hdl.handle.net/10204/4597
Lemmer Y, Semete B, Booysen L, Kalombo L, Katata L, Jones A, et al, Targeted nanodrug delivery systems for the treatment of Tuberculosis; 2010. http://hdl.handle.net/10204/4597 .
